Information

Summary : Pfizer and Ionis Pharmaceuticals announced that the former is abandoning its vupanorsen program for cardiovascular (CV) risk reduction and severe…

Summary : Drugmaker is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit…

Abstract: The European Commission has approved Pfizer`s first-of-its-kind oral Janus kinase (JAK) inhibitor  XELJANZ® (Tofacitinib) 5 mg twice daily for the treatment…

SUMMARY: The U.S. Food and Drug Administration today authorized marketing of EaseVRx, a prescription-use immersive virtual reality (VR) system that uses cognitive…

ABSTRACT: The introduction of “Sustainable Practices Badge” seeks to encourage the adoption of more sustainable practices by Brazil’s grain growers and it…